Hope for hair loss: new pill targets scarring alopecia
Disease control
Not yet recruiting
This study tests a daily pill called deucravacitinib in 20 adults with two types of scarring hair loss (CCCA and FFA). The goal is to see if the drug can reduce inflammation and scarring on the scalp over 48 weeks. Participants take the medication for the entire study period, so …
Phase: PHASE2 • Sponsor: Icahn School of Medicine at Mount Sinai • Aim: Disease control
Last updated Apr 24, 2026 16:20 UTC